Ιατρικά Άρθρα: Open-Label, Multicenter, Phase Ⅱ Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Τετάρτη 17 Οκτωβρίου 2018

Open-Label, Multicenter, Phase Ⅱ Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Condition: Over Survival
Intervention: Drug: Docetaxel and Cisplatin and Nimotuzumab
Sponsor: Sun Yat-sen University
Not yet recruiting

https://ift.tt/2yqWy9H

Ιατρικά Άρθρα

Ετικέτες

Τετάρτη 17 Οκτωβρίου 2018

Open-Label, Multicenter, Phase Ⅱ Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Multifunctional Two-Dimensional Bi<sub>2</sub>Se<sub>3</sub> Nanodiscs for Anti-Inflammatory Therapy of Inflammatory Bowel Diseases

Αναζήτηση αυτού του ιστολογίου

Αναφορά κατάχρησης